Icotidine (also known as SKF 93319) was developed as histamine H1- and H2-receptor antagonist and possessed antinociception properties. Due to its antagonist activity, was suggested that compound could have therapeutic in some inflammatory skin diseases such as the urticarias and mastocytosis.

Berlafenone (previously known as GK 23 G), a sodium channel antagonist was studied as a class Ic antiarrhythmic agent, but development has been discontinued.

Pecocycline, a synthetic tetracycline that was developed as an antibiotic. Information about the current use of this drug is not available.

Rilopirox (HOE 351) is a fungicidal antimycotic that was developed as an intravaginal antifungal with a long skin retention time and a strong killing effect on pathogenic yeasts. Its very low water solubility makes rilopirox a good candidate for an intravaginal antifungal. Potential applications may be in mucosal candida infections, tinea versicolor and seborrheic dermatitis. In addition, it has been suggested that rilopirox could be effective against oropharyngeal Candida infections, for example in AIDS patients. There is no information on current development of rilopirox.

FEZOLAMINE is a nontricyclic antidepressant. It acts as a serotonin, norepinephrine, and dopamine reuptake inhibitor, with a preference for the former neurotransmitter. It was found to be effective and well tolerated in clinical trials but was never marketed.

Heptaverine was used as a spasmolytic agent. Information about the current use of this compound is not available.

Hepzidine (BS 7051) is a compound, possessing antidepressive and anticholinergic properties.

Ebalzotan is a selective serotonin (5-HT1A) receptor agonist, was chosen by Astra in the early 1990s as a candidate drug for the treatment of depression and anxiety. It has a modest affinity for the 5-HT(7). In vivo, ebalzotan induced all the typical effects of a 5-HT(1A) receptor agonist in rats: it decreased 5-HT synthesis (5-HTP accumulation) and 5-HT turnover (measured as the ratio of 5-hydroxyindoleacetic acid/5-HT), increased corticosterone secretion, induced the 5-HT(1A) syndrome (flat body posture and forepaw treading), inhibited the cage-leaving response, and caused hypothermia. Ebalzotan had been in phase I clinical trial for the treatment of major depressive disorder. However, this study was discontinued.

Furterene is a diuretic of the aminopteridine series, with aldosterone antagonist activity. Furterene is able to antagonize aldosterone at the mineralocorticoid receptor in the kidneys. It thereby increases sodium excretion while inhibiting potassium excretion.